MX9709466A - Medicamento para inhibir el melanoma. - Google Patents

Medicamento para inhibir el melanoma.

Info

Publication number
MX9709466A
MX9709466A MX9709466A MX9709466A MX9709466A MX 9709466 A MX9709466 A MX 9709466A MX 9709466 A MX9709466 A MX 9709466A MX 9709466 A MX9709466 A MX 9709466A MX 9709466 A MX9709466 A MX 9709466A
Authority
MX
Mexico
Prior art keywords
melanoma
methods
inhibiting
inhibiting melanoma
hexamethyleneamino
Prior art date
Application number
MX9709466A
Other languages
English (en)
Other versions
MXPA97009466A (es
Inventor
Robert Alan Swift
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MXPA97009466A publication Critical patent/MXPA97009466A/es
Publication of MX9709466A publication Critical patent/MX9709466A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Se describe un método para inhibir el melanoma, que comprende el administrar a un humano en necesidad del mismo una cantidad efectiva de un compuesto que tiene la formula I, en donde R1 y R3 son independientemente hidrogeno, -CH3, (a) o (b), en donde Ar es fenilo opcionalmente sustituido; R2 se selecciona del grupo que consiste de pirrolidina, hexametilenamino, y piperidino; o una sal farmacéuticamente aceptable o solvato del mismo; solo o en combinacion con uno o más agentes inhibidores de melanoma.
MX9709466A 1995-06-06 1996-06-06 Medicamento para inhibir el melanoma. MX9709466A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/466,673 US5843974A (en) 1995-06-06 1995-06-06 Methods of inhibiting melanoma using Benzothiophenes as cytotoxic agents per se
US08466673 1995-06-06
PCT/US1996/009839 WO1996039135A1 (en) 1995-06-06 1996-06-06 Methods of inhibiting melanoma

Publications (2)

Publication Number Publication Date
MXPA97009466A MXPA97009466A (es) 1998-02-01
MX9709466A true MX9709466A (es) 1998-02-28

Family

ID=23852667

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9709466A MX9709466A (es) 1995-06-06 1996-06-06 Medicamento para inhibir el melanoma.

Country Status (16)

Country Link
US (1) US5843974A (es)
EP (1) EP0747053A3 (es)
JP (1) JPH11507371A (es)
KR (1) KR19990022364A (es)
CN (1) CN1192141A (es)
AU (1) AU702716B2 (es)
CA (1) CA2223157A1 (es)
CZ (1) CZ383197A3 (es)
EA (1) EA000680B1 (es)
HU (1) HUP9901093A3 (es)
IL (1) IL118574A0 (es)
MX (1) MX9709466A (es)
NO (1) NO975580D0 (es)
PL (1) PL323924A1 (es)
WO (1) WO1996039135A1 (es)
ZA (1) ZA964682B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6228850B1 (en) * 1997-09-30 2001-05-08 Dabur Research Foundation Antiangiogenic activity of betulinic acid and its derivatives
US6048847A (en) * 1997-09-30 2000-04-11 Dabur Research Foundation Use of betulinic acid and its derivatives for inhibiting cancer growth and a method of monitoring this
US6670345B1 (en) 1997-09-30 2003-12-30 Dabur Research Foundation Betulinic acid derivatives for inhabiting cancer growth and process for the manufacture of betulinic acid
PT1175433E (pt) 1999-05-04 2005-11-30 Strakan Int Ltd Glicosidos androgenos e sua actividade androgenica
WO2005084712A2 (en) * 2004-02-27 2005-09-15 Antisense Pharma Gmbh Use of an oligonucleotide or its active derivative for the preparation of a pharmaceutical composition for inhibiting the formation of metastases in cancer treatment
WO2005089443A2 (en) * 2004-03-19 2005-09-29 The Penn State Research Foundation Combinatorial methods and compositions for treatment of melanoma
JP6320382B2 (ja) 2012-08-13 2018-05-09 ザ ロックフェラー ユニヴァーシティ メラノーマの処置および診断
AU2015204572B2 (en) 2014-01-10 2020-07-30 Inspirna, Inc. LXR agonists and uses thereof
US9758786B2 (en) 2016-02-09 2017-09-12 Autotelic, Llc Compositions and methods for treating pancreatic cancer
WO2019104062A1 (en) 2017-11-21 2019-05-31 Rgenix, Inc. Polymorphs and uses thereof
US11174220B2 (en) 2019-12-13 2021-11-16 Inspirna, Inc. Metal salts and uses thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4133814A (en) * 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
US4380635A (en) * 1981-04-03 1983-04-19 Eli Lilly And Company Synthesis of acylated benzothiophenes
US4656187A (en) * 1981-08-03 1987-04-07 Eli Lilly And Company Treatment of mammary cancer
US5075321A (en) * 1987-03-24 1991-12-24 University Of Pennsylvania Methods of treating diseases characterized by interactions of IgG-containing immune complexes with macrophage Fc receptors using antiestrogenic benzothiophenes
TW366342B (en) * 1992-07-28 1999-08-11 Lilly Co Eli The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss
JPH07149638A (ja) * 1993-10-15 1995-06-13 Eli Lilly & Co 耐性新生物の治療法
CN1058390C (zh) * 1993-10-15 2000-11-15 伊莱利利公司 苯并噻吩类化合物的用途
US5457113A (en) * 1993-10-15 1995-10-10 Eli Lilly And Company Methods for inhibiting vascular smooth muscle cell proliferation and restinosis
US5476862A (en) * 1993-12-21 1995-12-19 Eli Lilly And Company Methods of increasing thrombomodulin expression
US5622975A (en) * 1995-06-01 1997-04-22 Eli Lilly And Company Methods for inhibiting vascular smooth muscle cell migration
US5726168A (en) * 1995-10-12 1998-03-10 Eli Lilly And Company Lipophilic benzothiophenes
US5780497A (en) * 1996-04-19 1998-07-14 American Home Products Corporation 2-phenyl-1- 4-(amino-1-yl-alk-1-ynyl)-benzyl!-1H-indol-5-ols as estrogenic agents

Also Published As

Publication number Publication date
CN1192141A (zh) 1998-09-02
NO975580L (no) 1997-12-03
EA000680B1 (ru) 2000-02-28
CZ383197A3 (cs) 1998-07-15
AU702716B2 (en) 1999-03-04
HUP9901093A2 (hu) 1999-10-28
HUP9901093A3 (en) 2000-02-28
CA2223157A1 (en) 1996-12-12
NO975580D0 (no) 1997-12-03
ZA964682B (en) 1997-12-05
KR19990022364A (ko) 1999-03-25
EA199800015A1 (ru) 1998-06-25
PL323924A1 (en) 1998-04-27
AU6109096A (en) 1996-12-24
WO1996039135A1 (en) 1996-12-12
EP0747053A2 (en) 1996-12-11
JPH11507371A (ja) 1999-06-29
EP0747053A3 (en) 1997-01-29
US5843974A (en) 1998-12-01
IL118574A0 (en) 1996-10-16

Similar Documents

Publication Publication Date Title
MY132056A (en) Methods of inhibiting physiological conditions associated with an excess of neuropeptide y.
MY132251A (en) Methods of inhibiting cell-cell adhesion
MX9701325A (es) Metodos para inhibir la mucositis ulcerativa.
MX9701329A (es) Metodos para la inhibicion de la replicacion viral.
AU7578794A (en) Methods for inhibiting endometriosis
MX9701360A (es) Metodos para la inhibicion de la desmielinizacion y las enfermedades de la dismielinizacion.
MY112973A (en) Methods for inhibiting vascular smooth muscle cell migration
UA27910C2 (uk) Засіб для підвищення експресії тромбомодуліну та підвищення активації протеїну с
MX9709466A (es) Medicamento para inhibir el melanoma.
MX9701334A (es) Metodos para inhibir la degeneracion de protesis oseas.
MY113406A (en) Methods of inhibiting physiological conditions associated with an excess of bradykinin
MX9701333A (es) Metodos para inhibir el daño neuronal.
MX9702148A (es) Metodos para inhibir la mitosis endometrial.
MX9701327A (es) Metodos para inhibir el cancer endometrial.
MX9701359A (es) Metodos para la inhibicion de la hiperplasia endometrial primaria.
MX9701331A (es) Metodos para mantener los dientes y los huesos bucales.
MX9705940A (es) Metodos y composiciones para inhibir los efectos de la interleucina 6.
MX9706520A (es) Metodos para inhibir el cancer de ovario.
MX9709536A (es) Metodo para reducir el factor de transcripcion bef-1.
MX9709651A (es) Metodos para modulacion del factor de transcripcion nf-kb.
MX9705215A (es) Uso de 2-fenil-3-aroilbenzotiofenos para inhibir los efectos de la hormona del crecimiento.
MX9701328A (es) Metodos de reduccion de la cicatrizacion en la curacion de heridas.
MX9705537A (es) Metodos y composiciones para inhibir el efecto de los estrogenos del medio ambiente.
MX9705697A (es) Metodos para reducir los niveles de calcio del suero.
MX9806036A (es) Compuestos para inhibir tumores en el colon.